SCHEMBL4671883

SCHEMBL4671883

Cc1ccc(Cn2ccc(C(=O)C=C(O)c3nc[nH]n3)c2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 1/20 0.34
CYP19A1 P11511 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
TBXAS1 P24557 2/20 0.32
ALDH1A1 P00352 3/20 0.32
LMNA P02545 3/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
MAPT P10636 2/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 1/20 0.32
PLA2G4A P47712 1/20 0.31
PTGDR2 Q9Y5Y4 1/20 0.31
KDM4E B2RXH2 2/20 0.31
APEX1 P27695 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
POLB P06746 1/20 0.31
GAA P10253 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4679616 0.91 HRH3 (0.34) KLKB1CYP19A1TBXAS1ALDH1A1LMNA
SCHEMBL5899369 0.90 CYP2C19 (0.38) KLKB1CYP19A1TBXAS1POLB
SCHEMBL4677568 0.90 CYP19A1 (0.41) CYP19A1TBXAS1LMNASMN1; SMN2MAPT
SCHEMBL4671856 0.89 KDM5A (0.38) CYP19A1CYP11B1CYP11B2TBXAS1ALDH1A1
SCHEMBL4671326 0.89 KLKB1 (0.34) KLKB1CYP11B1CYP11B2TBXAS1
SCHEMBL4679492 0.88 TBXAS1 (0.35) KLKB1CYP19A1CYP11B1TBXAS1ALDH1A1
SCHEMBL4678580 0.83 KLKB1 (0.34) KLKB1CYP19A1CYP11B1CYP11B2
SCHEMBL4674940 0.82 KLKB1 (0.42) KLKB1ALDH1A1KDM4EPOLB
SCHEMBL4677701 0.82 KDM4C (0.42) CYP11B1CYP11B2NPC1RAB9ATDP1
SCHEMBL5899377 0.81 NPC1 (0.34) CYP19A1LMNASMN1; SMN2NPC1PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 KLKB1 3843/4885CYP19A1 96/4885CYP11B1 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.